Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 9/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745448 | 0.79 | NR1I2 (0.63) | NR1I2OPRM1DRD3OPRD1BCHE | |
| SCHEMBL13745891 | 0.78 | NR1I2 (0.65) | NR1I2OPRM1DRD3OPRD1BCHE | |
| SCHEMBL17087224 | 0.78 | NR1I2 (0.45) | NR1I2OPRM1DRD3OPRD1CA12 | |
| SCHEMBL17087299 | 0.77 | NR1I2 (0.43) | NR1I2OPRM1DRD3OPRD1BCHE | |
| SCHEMBL13753857 | 0.77 | CA2 (0.41) | NR1I2OPRM1DRD3OPRD1CYP1A2 | |
| SCHEMBL13745929 | 0.67 | CA2 (0.40) | CYP1A2CA12CA1CA2CA4 | |
| SCHEMBL13735173 | 0.65 | NR1I2 (0.73) | NR1I2OPRM1DRD3OPRD1CYP1A2 | |
| SCHEMBL17087355 | 0.65 | NR1I2 (0.37) | NR1I2OPRM1DRD3OPRD1CYP1A2 | |
| SCHEMBL18659884 | 0.64 | NR1I2 (0.77) | NR1I2OPRM1DRD3OPRD1BCHE | |
| SCHEMBL18659662 | 0.63 | NR1I2 (0.79) | NR1I2OPRM1DRD3OPRD1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
| WO-2007017768-A2 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2007-02-15 | — | — | WO | disclosed |
| EP-1752143-A1 | Novel uses for drugs targeting glutamine synthetase | NewThera (FR) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | GLUL, GLS2, ASNS | NR1I2 516/4885OPRM1 224/4885DRD3 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.